Themis Medicare Faces ₹13.32 Cr Tax Demand, Plans Appeal

Themis Medicare Ltd has received a notice from the Income Tax Department demanding payment of outstanding taxes totaling ₹13.32 crore for assessment years 2017-18, 2018-19, and 2020-21.
The largest component of this demand, ₹8.71 crore, pertains to assessment year 2017-18, followed by ₹4.17 crore for 2018-19 and ₹0.44 crore for 2020-21.

Tax Demand and Company Response
On March 25, 2026, Themis Medicare Ltd announced it received a tax demand notice from the Income Tax Department. The aggregate demand stands at ₹13.32 crore, spread across three assessment years. The company stated it is actively preparing to file an appeal against this notice. Management expressed confidence in its ability to defend the matter before higher appellate forums. Crucially, Themis Medicare has assured stakeholders that this tax demand is not expected to adversely impact its overall financial position or operational continuity.

Industry Context
This tax demand adds to the compliance and regulatory pressures faced by companies in the pharmaceutical sector. A significant tax demand can affect cash flow and profitability if not resolved favorably. The Indian pharmaceutical industry has been under increased scrutiny from tax authorities recently. Bodies like the Directorate General of GST Intelligence (DGGI) are intensifying their focus on suspected tax evasion within the sector, driven by issues such as non-payment of GST on brand transfer sales, claims of fake input tax credit (ITC), and non-compliance with reverse charge mechanisms. This indicates a sector-wide tightening of tax compliance measures.

Company's Path Forward
Themis Medicare will dedicate resources to preparing and filing an appeal against the tax demand. Management's confidence suggests they have identified legal or factual grounds to challenge it. The company's operations and financial strategy are expected to remain on track, according to its assurance. Shareholders will await progress on the appeal.

Potential Risks
The primary risk is an unfavorable outcome in the appeal process, which could lead to the demand becoming payable and impacting finances. While the company expects no adverse impact, prolonged litigation can still consume management time and resources. Increased tax assessments can sometimes signal closer regulatory oversight in the future.

Peer Actions
Several major Indian pharmaceutical companies have recently faced significant tax demands and penalties. Sun Pharmaceutical Industries, for instance, was penalized ₹160.2 crore, while Aurobindo Pharma received a demand of ₹77.61 crore. Divi's Laboratories is also contesting tax adjustments totaling over $60 million. These instances show that tax assessments are common challenges within the pharma sector, with companies often resorting to appeals.

Recent Financial Performance
For Q4 FY25, Themis Medicare reported total income of ₹98.92 crore and a Profit After Tax of ₹6.64 crore. In the latest reported six-month period, net sales contracted by 20.25% to ₹168.12 crore, and profit after tax declined by 50.60% to ₹7.32 crore.

Key Updates for Investors
Investors will track the company's progress in filing the appeal and any updates from the Income Tax Department. Management's commentary on the appeal's prospects during future investor calls or filings will also be important. Any adverse developments or positive resolutions concerning the tax demand, alongside the company's ability to maintain its growth trajectory and financial stability amidst regulatory challenges, are key areas to watch.